capecitabine and trastuzumab

Phase 3Monoclonal antibody

FFudan University

capecitabine and trastuzumab is one of 42 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerUnknown status

Patients With Locally Advanced Rectal CancerNot yet recruiting

Locally Advanced Colon CancerRecruiting

Adjuvant ChemotherapyNot yet recruiting

Breast CancerPhase 2

Unknown status

Patients With Locally Advanced Rectal CancerPhase 2

Not yet recruiting

Locally Advanced Colon CancerPhase 3

Recruiting

Adjuvant ChemotherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

capecitabine and trastuzumab

FFudan University

Phase 3

4 2

Lexiscan

Astellas

Preclinical

1 3

Vfend

PPrism Pharmaceuticals

Preclinical

—4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 6

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 7

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

1 8

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

1 9

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Patients With Locally Advanced Rectal Cancer

NCT04443543

Q2 2027

Phase 3Recruiting

Locally Advanced Colon Cancer

NCT03125980

Q4 2028

Phase 2Not yet recruiting

Adjuvant Chemotherapy

NCT07296666

Q3 2031

Phase 2Active, not recruiting

Breast Cancer

NCT04383275

Clinical

Trials by Indication[1]

Breast Cancer4 trials

An All-Oral Combination of Capecitabine and Cyclophosphamide in Patients With Metastatic Breast Cancer (MBC)

Unknown status·FFudan University·Phase 2·NCT00589901·60 enrolled

Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)

Completed·FFudan University·Phase 2·NCT01380808·100 enrolled

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

Not yet recruiting·FFudan University·Phase 2·NCT04922008·356 enrolled

Show 1 more trial

An Open-label,Phase II Study Evaluating the Efficacy and Safety of Trastuzumab Combined With Oral Chemotherapy or Endocrine Therapy in Patients With HER-2 Positive Stage I Breast Cancer

Active, not recruiting·FFudan University·Phase 2·NCT04383275·367 enrolled

Locally Advanced Colon Cancer2 trials

Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

Recruiting·FFudan University·Phase 3·NCT03125980·1,370 enrolled

Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients

Unknown status·FFudan University·Phase 2·NCT02415829·55 enrolled

Adjuvant Chemotherapy1 trial

Adjuvant Chemotherapy for BTC Based on 3D-PTA

Not yet recruiting·FFudan University·Phase 2·NCT07296666·98 enrolled

Colorectal Cancer1 trial

Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)

Unknown status·GGuangdong Provincial People's Hospital·Phase 2·NCT00997685·110 enrolled

Adjuvant Treatment1 trial

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Completed·FFudan University·Phase 2·NCT05254847·65 enrolled

1 more indication

Patients With Locally Advanced Rectal Cancer1 trial

An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

Not yet recruiting·FFudan University·Phase 2·NCT04443543·222 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for capecitabine and trastuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — capecitabine and trastuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for capecitabine and trastuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: FFudan University

capecitabine and trastuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2028

Q3 2031

Trials by Indication[1]

Breast Cancer4 trials

Locally Advanced Colon Cancer2 trials

Adjuvant Chemotherapy1 trial

Colorectal Cancer1 trial

Adjuvant Treatment1 trial

Patients With Locally Advanced Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News